These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35317892)

  • 1. How satisfactory is on-demand icatibant from the patients' perspective in real life?
    Beyaz S; Demir S; Oztop N; Colakoglu B; Buyukozturk S; Gelincik A
    Allergy Asthma Proc; 2022 Mar; 43(2):148-154. PubMed ID: 35317892
    [No Abstract]   [Full Text] [Related]  

  • 2. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
    Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O;
    Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients.
    Federici C; Perego F; Borsoi L; Crosta V; Zanichelli A; Gidaro A; Tarricone R; Cicardi M
    BMJ Open; 2018 Jul; 8(7):e022291. PubMed ID: 30061443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey.
    Maurer M; Bork K; Martinez-Saguer I; Aygören-Pürsün E; Botha J; Andresen I; Magerl M
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):163-169. PubMed ID: 30176179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
    Otani IM; Lumry WR; Hurwitz S; Li HH; Craig TJ; Holtzman NS; Iandoli MI; Tucker J; Riedl MA; Zuraw BL; Banerji A
    J Allergy Clin Immunol Pract; 2017; 5(2):442-447.e1. PubMed ID: 27818136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries.
    Caballero T; Aberer W; Longhurst HJ; Maurer M; Zanichelli A; Perrin A; Bouillet L; Andresen I;
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1214-1222. PubMed ID: 28370444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study.
    Grumach AS; Henriques MT; Bardou MLD; Pontarolli DA; Botha J; Correa M;
    An Bras Dermatol; 2022; 97(4):448-457. PubMed ID: 35654647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
    Farkas H; Reshef A; Aberer W; Caballero T; McCarthy L; Hao J; Nothaft W; Schranz J; Bernstein JA; Li HH
    J Allergy Clin Immunol Pract; 2017; 5(6):1671-1678.e2. PubMed ID: 28601641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.
    Maurer M; Longhurst HJ; Fabien V; Li HH; Lumry WR
    Allergy Asthma Proc; 2014; 35(5):377-81. PubMed ID: 25198193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
    Longhurst HJ; Zanichelli A; Caballero T; Bouillet L; Aberer W; Maurer M; Fain O; Fabien V; Andresen I;
    Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
    Hide M; Horiuchi T; Ohsawa I; Andresen I; Fukunaga A
    Allergol Int; 2021 Jan; 70(1):45-54. PubMed ID: 32919903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks.
    Bernstein JA; Tyson C; Relan A; Adams P; Magar R
    J Manag Care Spec Pharm; 2020 Feb; 26(2):203-210. PubMed ID: 31841366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
    Lumry WR; Farkas H; Moldovan D; Toubi E; Baptista J; Craig T; Riedl M
    Int Arch Allergy Immunol; 2015; 168(1):44-55. PubMed ID: 26556097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy.
    Hakl R; Kuklínek P; Krčmová I; Králíčková P; Freiberger T; Janků P; Vlková M; Litzman J
    J Clin Immunol; 2018 Oct; 38(7):810-815. PubMed ID: 30280305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals.
    Hernández Fernandez de Rojas D; Ibañez E; Longhurst H; Maurer M; Fabien V; Aberer W; Bouillet L; Zanichelli A; Caballero T;
    Int Arch Allergy Immunol; 2015; 167(1):21-8. PubMed ID: 26112099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-administration of icatibant in acute attacks of Type I hereditary angioedema: A case report and review of hereditary angioedema.
    Piras V; Alves F; Gonçalo M
    Dermatol Ther; 2019 Nov; 32(6):e13098. PubMed ID: 31579975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study.
    Campos RA; Valle SO; França AT; Cordeiro E; Serpa FS; Mello YF; Malheiros T; Toledo E; Mansour E; Fusaro G; Grumach AS
    Sao Paulo Med J; 2014; 132(5):261-5. PubMed ID: 25054967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema.
    Maurer M; Aberer W; Caballero T; Bouillet L; Grumach AS; Botha J; Andresen I; Longhurst HJ;
    Clin Exp Allergy; 2022 Sep; 52(9):1048-1058. PubMed ID: 35861129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study.
    Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y
    Allergol Int; 2020 Apr; 69(2):268-273. PubMed ID: 31672405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Icatibant Outcome Survey in Patients with Hereditary Angioedema: Experience in Israel Compared with Other Countries.
    Toubi E; Kivity S; Graif Y; Reshef A; Botha J; Andresen I
    Isr Med Assoc J; 2018 Apr; 20(4):227-232. PubMed ID: 29629730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.